SUMMARY CMI

Droperidol Panpharma

Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.

1. Why am I using Droperidol Panpharma?

Droperidol Panpharma contains the active ingredient droperidol. Droperidol Panpharma is used in anaesthesia for surgery and some diagnostic procedures. It is also used to help manage severe agitation, aggression and over-activity in some diseases of the brain. For more information, see Section 1 Why am I using Droperidol Panpharma? in the full CMI.

2. What should I know before I use Droperidol Panpharma?

Do not use if you have ever had an allergic reaction to droperidol or any of the ingredients listed at the end of the CMI. There are several circumstances in which Droperidol Panpharma should not be used or when it should only be used with additional caution. Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding. For more information, see Section 2. What should I know before I use Droperidol Panpharma? in the full CMI.

3. What if I am taking other medicines?

Some medicines must be avoided if Droperidol Panpharma has been given. Other medicines may interfere with Droperidol Panpharma and affect how it works A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

4. How do I use Droperidol Panpharma?

• Droperidol Panpharma should be given by a healthcare professional in a medical facility where appropriate monitoring facilities are available.
• Your doctor will give you Droperidol Panpharma by injecting it into a muscle or slowly into a vein. Your doctor will monitor your response and may change the dose of Droperidol Panpharma if you need additional treatment with it.

More instructions can be found in Section 4. How Droperidol Panpharma is given? in the full CMI.

5. What should I know while using Droperidol Panpharma?

For more information, see Section 5. What should I know while using Droperidol Panpharma? in the full CMI.

6. Are there any side effects?

Like all medicines, Droperidol Panpharma can cause side effects. Tell your doctor or pharmacist as soon as possible if you do not feel well while you are taking Droperidol Panpharma.

For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.

FULL CMI

Droperidol Panpharma

Active ingredient(s): droperidol

Consumer Medicine Information (CMI)

This leaflet provides important information about using Droperidol Panpharma. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using Droperidol Panpharma.

Where to find information in this leaflet:

1. Why am I using Droperidol Panpharma?
2. What should I know before I use Droperidol Panpharma?
3. What if I am taking other medicines?
4. How Droperidol Panpharma is given?
5. What should I know while using Droperidol Panpharma?
6. Are there any side effects?
7. Product details

1. Why am I using Droperidol Panpharma?

Droperidol Panpharma contains the active ingredient Droperidol. Droperidol Panpharma Injection is a tranquilliser used to:

• calm patients before surgery and some diagnostic procedures
• reduce nausea and vomiting which may occur with anaesthesia
• help produce or maintain anaesthesia
• help reduce anxiety and pain when used with strong pain killers (opioids) in anaesthesia
• help manage severe agitation, aggression and over-activity in brain diseases associated with psychosis or other states of intense, unusual excitement in adults.

There is not enough information to recommend the use of Droperidol Panpharma for children under the age of 2 years.

Ask your doctor if you have any questions about why this medicine has been prescribed for you.

Your doctor may have prescribed it for another reason.

2. What should I know before I use Droperidol Panpharma?

Warnings

Droperidol Panpharma should not be used if you have:

• an allergy to droperidol, or any of the ingredients listed at the end of this leaflet.
• severe drowsiness and slowness as a result of brain disease or damage
• Parkinson's disease
• Pheochromocytoma, a type of tumour, which causes high blood pressure
• Low levels of salt in your blood
• A rare heart disorder known as QT prolongation.
  Sometimes this runs in families or can be caused by some medication or medical conditions

Always check the ingredients to make sure you can use this medicine.

Droperidol Panpharma Injection should not be used if you are intoxicated with alcohol.

Check with your doctor if you:

• have any other medical conditions
• take any medicines for any other condition

Tell your doctor if you have or have had:

• heart disease
• a family history of sudden death
• kidney disease
• lung disease
• dementia, if you are over 65 years of age
• history of blood clots or strokes
• any condition associated with electrolyte disturbances, including persistent vomiting or diarrhoea, alcohol abuse or eating disorders
• epilepsy or convulsions
• sleep apnoea, a sleep disorder where breathing temporarily stops and starts while you sleep.

During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

Pregnancy and breastfeeding

Tell your doctor if you are pregnant or plan to become pregnant.

Droperidol Panpharma should only be used during pregnancy if the benefits outweigh the risks to you and your baby.

Ask your doctor to discuss with you the risks and benefits of using Droperidol Panpharma during pregnancy.

Talk to your doctor if you are breastfeeding or intend to breastfeed.

3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines must be avoided if Droperidol Panpharma has been given. These include medicines known to cause QT prolongation, including:

• some medicines that act on the heart, such as quinidine, disopyramide, procainamide, amiodarone, sotalol and bepridil
• some medicines used to treat depression, such as maprotiline and amitriptyline
• some medicines used to treat mental illness, such as phenothiazines, pimozide and sertindole
• some antihistamines used to treat allergies or hay fever, such as astemizole and terfenadine
• cisapride, a medicine used to treat certain digestive problems
• halofantrine, a medicine used to treat malaria
• sparfloxacin, an antibiotic used to treat lung infections.

Some medicines may interfere with Droperidol Panpharma and affect how it works.

Your doctor also needs to know if you are taking:

• medicines that can increase your risk of electrolyte disturbance, such as laxatives, some steroids, some diuretics (water tablets), or insulin in some settings
• alcohol or medicines that make you feel drowsy or slow to react, such as sleeping tablets, tranquillisers or strong pain killers
• medicines used to treat high blood pressure
• medicines used to treat epilepsy, such as phenobarbitone, carbamazepine or phenytoin
• medicines used to treat Parkinson's disease such, as levodopa, bromocriptine, lisuride

Check with your doctor or pharmacist if you are not sure about what medicines, vitamins or supplements you are taking and if these affect Droperidol Panpharma.

4. How Droperidol Panpharma is given?

Droperidol Panpharma will be given to you by a healthcare professional in a medical facility where appropriate monitoring facilities are available.

If necessary, a single dose of Droperidol Panpharma can be given for the management of acute mania or severe agitation outside the hospital setting provided you are transferred immediately to a hospital setting.

How much to use

Your doctor will decide how much Droperidol Panpharma to give you based on many factors including your age, body weight, medical history, other medicines you are receiving and why you are receiving Droperidol Panpharma.

How it is used

Your doctor will give you Droperidol Panpharma by injecting it into a muscle or slowly into a vein.

If you use too much Droperidol Panpharma

As Droperidol Panpharma Injection is usually given to you in a hospital under the supervision of a doctor, it is unlikely that you will receive an overdose.

Symptoms of an overdose may include:

• unusual movements, including trembling and shaking of the hands and fingers, twisting movements of the body, shuffling walk and stiffness of the arms and legs
• uncontrollable movements
• dizziness, light headedness
• extreme drowsiness
• shallow breathing
• fits
• irregular heartbeat.

If you think you may have been given an overdose, you should immediately:

• contact your doctor, or
• phone the Poisons Information Centre (by calling 13 11 26 in Australia or 0800 764 766 in New Zealand or go to the Emergency Department at your nearest hospital.

You should do this even if there are no signs of discomfort or poisoning.

5. What should I know while using Droperidol Panpharma?

Things you should do

If you are about to be started on any new medicine, remind your doctor and pharmacist that you have been given Droperidol Panpharma Injection.

Tell any other doctors, nurses or other health professionals who treat you that you have been given Droperidol Panpharma.

If you become pregnant after being treated with this medicine, tell your doctor.

Things to be careful of

If you feel light-headed, dizzy or faint when getting out of bed or standing up, get up slowly.

Standing up slowly, especially when you get up from bed or chairs, will help your body get used to the change in position and blood pressure. If this problem continues or gets worse, talk to your doctor.

Driving or using machines

Be careful before you drive or use any machines or tools until you know how Droperidol Panpharma affects you.

This medicine may cause dizziness and drowsiness in some people. If you have any of these symptoms, do not drive, operate machinery or do anything else that could be dangerous.

Drinking alcohol

Tell your doctor if you drink alcohol.

Be careful drinking alcohol after you have been given this medicine.

If you drink alcohol, dizziness or drowsiness may be worse.

Looking after your medicine

Droperidol Panpharma will be stored in the surgery, pharmacy or ward of a hospital. The injection is kept in a cool dry place, protected from light, where the temperature stays below 30°C.

Droperidol Panpharma Injection will only be opened when it is time for you to have the injection.

Your doctor or nurse will check to ensure it is a clear, colourless solution, free of particles, and that it is not past its expiry date.

Getting rid of any unwanted medicine

The hospital staff will dispose of any leftover Droperidol Panpharma for you.

Do not use this medicine after the expiry date.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

If you are over 65 years of age, you may be at increased risk of developing some side effects.

See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects.

Less serious side effects

Serious side effects

Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell.

Other side effects not listed here may occur in some people.

Reporting side effects

After you have received medical advice for any side effects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems. By reporting side effects, you can help provide more information on the safety of this medicine.

Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

7. Product details

Droperidol Panpharma is a prescription medicine and is only administered under a doctor's supervision.

What Droperidol Panpharma contains

Do not take this medicine if you are allergic to any of these ingredients.

What Droperidol Panpharma looks like

Droperidol Panpharma Injection is a clear colourless liquid in an amber glass ampoule. It is supplied in packs of 5, 10 or 50 ampoules. Note: Not all carton sizes may be marketed.

Each ampoule contains:

• Droperidol Panpharma 1.25 mg/2.5 mL (0.5 mg/mL): AUST R 238346
• Droperidol Panpharma 2.5 mg/1 mL (2.5 mg/mL): AUST R 238342
• Droperidol Panpharma 5 mg/2 mL (2.5 mg/mL): AUST R 238347

Who distributes Droperidol Panpharma

Droperidol Panpharma Injection is supplied in Australia by:

Panpharma Australia Pty Limited
2152 Castlereagh Road
Penrith NSW 2750
Australia

Distributed by:

Omegapharm Pty Ltd
P O Box 18
Ormond VIC 3204
Australia

This leaflet was prepared in March 2025.

Published by MIMS July 2025

Notes

Distributed by Omegapharm Pty Ltd

1 Name of Medicine

Droperidol.

2 Qualitative and Quantitative Composition

Droperidol Panpharma comes in two strengths:
Droperidol Panpharma 1.25 mg/2.5 mL contains 0.5 mg of droperidol in 1 mL of solution.
Droperidol Panpharma 2.5 mg/1 mL and 5.0 mg/2.0 mL contains 2.5 mg of droperidol in 1 mL of solution.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Solution for injection.
Droperidol Panpharma 0.5 mg/1 mL or 2.5 mg/1 mL is a cream-coloured, light-sensitive, crystalline, hygroscopic substance, slightly soluble in water and alcohol, and soluble in aqueous solutions with pH < 4.

4 Clinical Particulars

4.1 Therapeutic Indications

Anaesthesia.

Psychiatry.

4.2 Dose and Method of Administration

Dosage should be individualised. Some of the factors to be considered in determining the dose are age, body weight, physical status, underlying pathological condition, use of other drugs, type of anaesthesia to be used and the surgical procedure involved.
Vital signs should be monitored routinely. To minimise the risk of ventricular arrhythmia, an electrocardiograph (ECG) should be performed and examined for evidence of QT prolongation before any operation commences. ECG monitoring should continue during the surgical procedure and subsequently for a period of time consistent with best medical judgement. This should be at least 7 hours after the end of the procedure. (See Section 4.3 Contraindications; Section 4.4 Special Warnings and Precautions for Use.)
Product is for single use in one patient only. Discard any residue.

Anaesthesia.

1. Premedication.

2. Adjunct to general anaesthesia.

3. Use without a general anaesthetic in diagnostic and minor surgical procedures.

Note.

4. Adjunct to regional anaesthesia.

Psychiatry.

Intravenous administration.

4.3 Contraindications

Droperidol Panpharma is contraindicated in:
Known hypersensitivity to this drug or its metabolites;
Severe central nervous system depression;
Comatose states from any cause;
Parkinson's disease;
Phaeochromocytoma;
Breast feeding.
Droperidol Panpharma should not be used in female patients with a QTc of greater than 450 msec or male patients with a QTc of greater than 440 msec (see Section 4.4 Special Warnings and Precautions for Use).
Droperidol Panpharma is contraindicated in patients with acquired long QT interval, such as that associated with concomitant use of drugs known to prolong the QT interval, known hypokalaemia, or hypomagnesaemia, or clinically significant bradycardia (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions).
Droperidol Panpharma is also contraindicated in patients with known congenital long QT interval or family history of congenital long QT syndrome.
Relative contraindication: acute alcohol intoxication.

4.4 Special Warnings and Precautions for Use

Fluids and other counter measures to manage hypotension should be readily available.
The benefits of using Droperidol Panpharma should be weighed against the potential risk. Droperidol Panpharma should only be used under appropriate medical supervision.
Patients with, or suspected of having, the following risk factors for cardiac arrhythmia should be carefully evaluated prior to the administration of Droperidol Panpharma:
A history of significant cardiac disease, including serious ventricular arrhythmia, second or third degree atrioventricular block, sinus node dysfunction, congestive heart failure or ischaemic heart disease and left ventricular hypertrophy;
A family history of sudden death;
Renal failure (particularly with chronic dialysis);
Significant chronic obstructive pulmonary disease and respiratory failure;
Risk factors for electrolyte disturbances as seen in patients taking laxatives, glucocorticoids, potassium-wasting diuretics, in association with the administration of insulin in acute settings or in patients with persistent vomiting and/or diarrhoea. In these patients, an ECG and an assessment of serum electrolytes (potassium and magnesium) and renal function should be performed as part of this evaluation and the presence of QT prolongation excluded prior to administration of droperidol. Continuous pulse oximetry should be performed in patients with identified or suspected risk of ventricular arrhythmia and should continue for 30 minutes following single i.v. administration. In a hospital setting, ECG monitoring should be started, when possible, before the administration of Droperidol Panpharma for anaesthesia (see Section 4.3 Contraindications). For patients with acute mania or agitation, it is recognised that performing an ECG prior to the initial dose(s) may be difficult. However, an ECG should be performed as soon as the patient's acute symptoms have subsided. Although the possibility of developing QT prolongation and torsade de pointes with the use of Droperidol Panpharma is low, ECG monitoring and full cardiac resuscitation facilities should be available.
Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with Droperidol Panpharma and preventive measures undertaken.
Outside the hospital setting, Droperidol Panpharma should only be used for the management of the psychiatric crisis e.g. acute mania or severe agitation. A single injection should be administered intramuscularly (not greater than 5 mg) and the patient should then be transferred immediately to a hospital facility by an ambulance equipped for cardiac resuscitation.
As with other CNS depressant drugs, patients who have received Droperidol Panpharma should have appropriate surveillance.
Patients with a history of alcohol abuse, or recent high intakes, are at the risk of increased arrhythmia.
If Droperidol Panpharma is administered with a narcotic analgesic, the user should familiarise himself with the special properties of each drug, particularly with the widely differing durations of action. In addition, when such a combination is used, resuscitative equipment and a narcotic antagonist should be readily available to manage apnoea.
Narcotic analgesics may cause muscle rigidity, particularly involving the muscles of respiration. This effect is related to the speed of injection. Its incidence can be reduced by the use of slow intravenous injection. Once the effect occurs, it is managed by the use of assisted or controlled respiration and by a neuromuscular blocking drug if necessary.
The respiratory depressant effect of narcotics persists longer than their measured analgesic effect. When used with Droperidol Panpharma, the total dose of all narcotic analgesics administered should be considered by the practitioner before ordering narcotic analgesics during recovery from anaesthesia. It is recommended that narcotics, when required, be used initially in reduced doses as low as 1/4 to 1/3 of those usually recommended.
Caution is advised if Droperidol Panpharma is given concomitantly with strong CYP1A2 and CYP3A4 inhibitors.

Use in psychiatry.

Use in anaesthesia.

Uses in patients with the following states.

Sleep apnoea.

Use in hepatic impairment.

Use in renal impairment.

Use in the elderly.

Paediatric use.

Effects on laboratory tests.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Drugs known to prolong the QT interval are contraindicated with Droperidol Panpharma. Examples include certain antiarrhythmics, such as those of Class IA (such as quinidine, disopyramide and procainamide) and Class III (such as amiodarone and sotalol); tricyclic antidepressants (such as amitriptyline); certain tetracyclic antidepressants (such as maprotiline); certain antipsychotic medications (such as phenothiazines, pimozide and sertindole); certain antihistamines (such as astemizole and terfenadine); cisapride, bepridil, halofantrine and sparfloxacin.
Droperidol may potentiate the action of sedative drugs (barbiturates, benzodiazepines, morphinomimetics). The same applies to antihypertensive agents, so that orthostatic hypotension may ensue.
Like other sedative drugs, droperidol may potentiate respiratory depression caused by opioids. Since droperidol blocks dopamine receptors, it may inhibit the action of dopamine agonists, such as bromocriptine, lisuride, and L-dopa.
Theoretically, certain agents (e.g. phenobarbitone, carbamazepine, phenytoin), as well as smoking and alcohol consumption, which stimulate metabolising enzymes in the liver, may enhance the metabolic breakdown of neuroleptics, possibly necessitating adjustment of the dose.
Concomitant use of Droperidol Panpharma with CYP1A2 inhibitors and/or CYP3A4 inhibitors could decrease the rate of droperidol metabolism and prolong its pharmacological action.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

4.7 Effects on Ability to Drive and Use Machines

Droperidol Panpharma may impair mental and/or physical abilities for operating machinery or driving a motor vehicle. Patients should only drive or operate a machine if sufficient time has elapsed after the administration of droperidol, i.e. about 10 hours after a dose of up to 5 mg and 24 hours after higher doses.

4.8 Adverse Effects (Undesirable Effects)

Central nervous system.

Extrapyramidal reactions.

Neuroleptic malignant syndrome.

Other central nervous system effects.

Cardiovascular.

General.

Haematological.

Hepatic.

Skin and appendages.

Respiratory.

Endocrine.

Gastrointestinal.

Autonomic nervous system.

Reporting suspected adverse effects.

4.9 Overdose

Acute toxicity - the toxic dose in man is not known.

Symptoms of overdosage.

Treatment of overdosage.

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

Pharmacology in animals.

Pharmacology in humans.

Clinical trials.

5.2 Pharmacokinetic Properties

The absorption, metabolism and excretion of tritiated droperidol following intramuscular and intravenous administration have been studied in humans. Total radioactivity levels were measured in plasma, urine, and faeces.

Absorption.

Distribution.

Metabolism.

Excretion.

5.3 Preclinical Safety Data

Genotoxicity.

Carcinogenicity.

6 Pharmaceutical Particulars

6.1 List of Excipients

Mannitol, tartaric acid, sodium hydroxide, water for injections.

6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 30°C. Protect from light.

6.5 Nature and Contents of Container

Droperidol Panpharma 0.5 mg/mL is presented in the following: as a 3 mL ampoule in a carton of 5 or 10; each ampoule contains 1.25 mg droperidol. Not all carton sizes may be marketed.
It contains 0.5 mg/mL droperidol, mannitol and tartaric acid in water for injections, together with sodium hydroxide for pH adjustment.
Droperidol Panpharma 2.5 mg/mL is presented in the following: 1 mL ampoule in a carton of 5, 10 or 50; each ampoule contains 2.5 mg droperidol. Not all carton sizes may be marketed;
2 mL ampoule in a carton of 5, 10 or 50; each ampoule contains 5.0 mg droperidol. Not all carton sizes may be marketed.
It contains 2.5 mg/mL droperidol, mannitol and tartaric acid in water for injections, together with sodium hydroxide for pH adjustment.
Product is for single use in one patient only. Discard any residue.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

6.7 Physicochemical Properties

Chemical structure.

CAS number.

7 Medicine Schedule (Poisons Standard)

Schedule 4 - Prescription Only Medicine.

Summary Table of Changes